Cardiovascular events of Bruton's tyrosine kinase inhibitors: A real‐world study based on the United States Food and Drug Administration Adverse Event Reporting System database - Zhao - British Journal of Clinical Pharmacology - Wiley Online Library
We aimed to characterize the cardiovascular AEs of BTKIs reported in the US Food and Drug Administration (FDA) Adverse Event Reporting System, and to compare the cardiovascular risks of BTKIs. To read the full article, choose Open Athens “Institutional Login” and search for “Midlands Partnership”.
